Galantamine and CBT4CBT Pilot to Prevent Relapse.

Phase 0 Completed 6 enrolled Yale University National Institute on Drug Abuse (NIDA) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The investigators are proposing a randomized pilot feasibility study to evaluate the effects of galantamine versus placebo on preventing relapse to opioid use following tapering from methadone or buprenorphine maintenance (Medication Assisted Treatment, or MAT) among adults with opioid use disorder, with additional behavioral therapy (web-based cognitive behavioral therapy) provided across all conditions to help individuals successfully transition from MAT to a drug-free state.

Timeline

Start: 2018-05-01
Primary completion: 2019-02-28
Completion: 2019-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Galantamine	Small molecule	16 mg	—

Indications

No indication recorded.